Biosafety Level You must comply with your country’s regulations. : {{entry.product.biosafetyLevel == -1 ? '-' : entry.product.biosafetyLevel}} Tariff Code: {{entry.product.euTariffCode}}
Biosafety Level You must comply with your country’s regulations. : {{entry.product.biosafetyLevel == -1 ? '-' : entry.product.biosafetyLevel}} Tariff Code: {{entry.product.euTariffCode}}
Cancer models, research chemicals and reference materials
From early stage drug discovery through to method development, drug substance testing and product release.
TRC Cancer research chemicals and analytical standards
From kinase inhibitors, apoptosis inducers and cytokine modulators to isotopes and synthetic chemistry building blocks, TRC supports you from target identification to drug development and toxicology.
From advanced 3D organoids and immuno-oncology models to the largest global repository of cancer lines, ATCC provides an unparalleled collection of cancer tools for basic research and drug discovery.
Explore our range of reference materials for oncology drugs designed for quantitative analysis. Each comes with a detailed COA providing full transparency of product characterisation.
TRC Cancer research chemicals and analytical standards
ATCC Get closer to in vivo
Mikromol API and impurity reference standards
Cancer is a complex, multifactorial disease characterised by the unrestrained proliferation of cells which invade normal tissues and organs. Hanahan and Weinberg pioneered modern studies of cancer-related genetic aberrations and epigenetic changes in 2011, when they proposed 10 ‘Hallmarks’ for cancer research. These hallmarks include: evading growth suppressors, avoiding immune destruction, enabling replicative immortality, tumour-promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and mutation, sustaining proliferative signalling and resisting cell apoptosis. Meanwhile, advances in genomics and biochemistry precipitated identification of key drug targets including cyclin-dependent kinases (CDK) and PARP enzymes, telomerases, p53, as well as RTK’s such as EGFR and VEGF.
Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. We provide industry-leading life science tools - from biologically active small molecules to cellular models, such as classical cancer cell lines and 3D screening platforms for the development of personalised medicines. We also supply API and impurity research chemicals as well as primary pharmaceutical reference standards to support your method development and drug batch release.
Acquired resistance to EGF receptor inhibitor Osimertinib is a problem for patients with lung cancer. TRC research chemicals were used in an investigation into resistance mechanisms, highlighting a prominent role of AXL/SFK/AKT signalling pathway.
Supporting the development of more effective therapies
Acquired resistance to EGF receptor inhibitors remains an issue causing relapse of lung cancers. TRC research chemicals were used in proteomics work to probe the nature of protein networks that assemble around the EGF receptor in resistant cancers.
TRC research chemicals were used in this novel treatment study
Decades of research aiming to identify new treatments to reduce mortality rates in metastatic uveal melanoma (UM) are still progressing. TRC research chemicals were used in a trial of a promising novel treatment approach using spheroid models of UM.
